Citations

Clear

7 citation(s) found for "Li, Yuwen".

Transformable Renal Cancer Targeted Responsive Nanopeptide Probes Effectively Inhibit Renal Cancer Progression and Metastasis by Inhibiting Renal Blood Vessels and Cancer Cells
Kong, Bin , Wu, Xiu‐Hai, Li, Cong , Chen, Meiqun, Liu, Yuwen , Liu, Cunyao, Wang, Xinyue , Chen, Bogong, Zang, Jiahui, Jian, Lingrui, Shen, Jiachen , Yu, Jiaao, Wu, Qiang , Yang, Guang , Wang, Ziqi , Wang, Lu , Wang, Lu , Liu, Pan , Chen, Meiqun, Liu, Cunyao, Liu, Ming

Mayo Clinic

ACS Applied Materials & Interfaces | November 13, 2025 | Volume: 17 | Issue: 47 | Pages: 64232-64243

10.1021/acsami.5c16546 | PMID 41231680 Get It

Expert Curation of Somatic FLT3 Variants By the Clingen Somatic Hematologic Cancer Taskforce (ClinGen HCT)
Shao, Xiangqiang , Mani, Coumarane, He, Rong , Danos, Arpad , Sheta, Lana , Terraf, Panieh, Raca, Gordana , Williams, Heather , Blombery, Piers , Viswanatha, David S., Jiang, Nan , Vavra, Kevin C., Zhang, Liying , Li, Yuwen , Zhong, Yiming , Matthew, Mariam T, Deeb, Kristin K. , Zhang, Fengli , Liu, Jie , Zhao, Xiaonan, Kopp, Nathan , Pondugula, Santhi , Fakim, Yasmina Jaufeerally , Wu, David , Pullarkat, Sheeja T. , Kulkarni, Shashikant , Madhavan, Subha , Kanagal‐Shamanna, Rashmi , Xu, Xinjie , Kanagal-Shamanna, Rashmi , Rao, Shruti , Saliba, Jason , Kesserwan, Chimene A. , Eno, Celeste , Jiang, Nan, Shi, Zonggao , Li, Peng , Ouseph, Madhu M. , Thompson, Ella R. , Krysiak, Kilannin , Wagner, Alex H. , McCoy, Matthew , Zhao, Xiaonan, Ferrer, Alejandro , Zhang, Wenying , Griffith, Obi L. , Griffith, Malachi

Mayo Clinic

Blood | November 23, 2021 | Volume: 138 | Issue: Supplement 1 | Pages: 4387-4387

10.1182/blood-2021-153546 Get It

Abstract Clinical significance of somatic gene variants needs to be comprehensively characterized for their diagnostic, prognostic and/or therapeutic actionability in patient management. However, challenges remain due to discrepancies in interpretation and reporting of these somatic variants among different testing labs. Therefore, standardized curation, clinical interpretation and reporting of somatic variants in hematologic cancers is critical. To address this issue, the Hematologic Cancer Taskforce (HCT), composed of 52 multi-disciplinary experts including oncologists, molecular pathologists, lab directors, genomic scientists and biocurators, was formed in January 2020 within the ClinGen Somatic Cancer Clinical Domain Working Group (CDWG) with a goal to undertake systematic curation and evidence-based clinical interpretation of genes/somatic variants associated with hematologic malignancies. In collaboration with the Clinical Interpretation of Variants in Cancer (CIViC) (civicdb.org) knowledgebase, HCT members curate, edit, and verify Evidence Items for each variant extracted from peer-reviewed publications. Monthly discussions based on these Evidence Items lead to the preparation of variant Assertions, which summarize the state of the field consensus variant interpretation and include tiering based on the AMP/ASCO/CAP guidelines (PMID: 27993330). FMS-like tyrosine kinase 3 (FLT3) encodes a class III receptor tyrosine kinase expressed in hematopoietic cells. FLT3 mutations, including both internal tandem duplication (ITD) and mutations in the tyrosine kinase domain (TKD), are the most common mutations in acute myeloid leukemia (AML), occurring in approximately 30% of all AML cases. Implementing FLT3 tyrosine kinase inhibitors (TKIs) in different treatment regimens for FLT3 mutated AML patients has led to significantly improved overall survival. Type I FLT3 inhibitors, including midostaurin, gilteritinib, sunitinib, lestaurtinib, and crenolanib, bind to the ATP-binding site when the receptor is in active conformation. Type II FLT3 inhibitors, including sorafenib, ponatinib, and quizartinib, interact with a hydrophobic region directly adjacent to the ATP-binding domain that is only accessible when the receptor is inactive, which prevents receptor activation. Generally in AML cells, type I FLT3 inhibitors prevent activity for both ITD and TKD mutations, while Type II inhibitors target ITD but lack efficiency against TKD mutations. The development of TKD mutations in AML cells with ITD have proved to be a mechanism of acquired, or secondary resistance to Type II FLT3 inhibitors. The HCT is piloting curation assessments of FLT3 alterations, including ITD, TKD and non-TKD variants, in AML. So far, the HCT has curated 75 evidence items for FLT3 somatic variants. FLT3-ITD, as well as D835 and I836 were asserted as tier 1 level A variants based on the prediction of response to gilteritinib in relapsed/refractory AML (PMIDs: 27993330, 31665578, 28645776, 28516360, 27908881). Recent curation activities are focused on FLT3 D839G and N676K, as clinical trials using large AML patient cohorts are lacking in their ability to validate drug response/resistance associations of these two TKD variants due to their low frequency. Functional studies showed both variants result in increased proliferation and protection from apoptosis, supporting the oncogenic potential of these two variants (PMIDs: 26891877, 2468088). FLT3 D839G combined with ITD confers resistance to pexidartinib and ponatinib, both Type II FLT3 inhibitors (PMIDs: 25847190, 23430109). FLT3 N676K predicts response to the Type I FLT3 inhibitor, gilteritinib, when N676K is present alone or in combination with ITD. Interestingly, FLT3 N676K in the absence of ITD predicts response to sorafenib, a Type II FLT3 inhibitor (PMIDs: 32040554, 32984009). However, these results are mostly derived from in vitro studies. Two separate Tier II, Level D Assertions have been submitted for FLT3-ITD&D839G for its response to pexidartinib and ponatinib, and more evidence is being collected to form an Assertion for FLT3 N676K. The complexity of the prediction of response/resistance associated with FLT3 D839G and N676K supports the importance of evidence-based curation and collection for these variants in the context of the overall mutation profile, disease context and specific FLT3 TKIs to clearly define their clinical impact. Disclosures Pullarkat: Stemline Therapeutics: Honoraria.
Expert Curation of Somatic Variants in Hematological Malignancies By the Clingen Somatic Hematological Cancer Taskforce (ClinGen HCT)
Kanagal‐Shamanna, Rashmi , Terraf, Panieh, Raca, Gordana , Danos, Arpad , Mani, Coumarane, Williams, Heather , Jiang, Nan , Vavra, Kevin C., Zhang, Liying , Li, Peng , Li, Yuwen , Ouseph, Madhu M. , Zhong, Yiming , Hinceman, Nicole, He, Rong , Matthew, Mariam T, Deeb, Kristin K. , Zhang, Fengli , Liu, Jie , Viswanatha, David S., Blombery, Piers , Wu, David , Kulkarni, Shashikant , Madhavan, Subha , Xu, Xinjie , Kanagal-Shamanna, Rashmi , Rao, Shruti , Saliba, Jason , Shi, Zonggao , Thompson, Ella R. , Krysiak, Kilannin , Wagner, Alex H. , McCoy, Matthew

Mayo Clinic

Blood | February 8, 2021 | Volume: 136 | Issue: Supplement 1 | Pages: 23-23

10.1182/blood-2020-143028 Get It

Hematological malignancies comprise a genetically heterogeneous spectrum of diseases caused by abnormal proliferation or maturation of a variety of hematological cell lineages. Genomic abnormalities including chromosomal translocations, copy number variations and sequence level gene mutations underlie the pathogenesis of these disorders and frequently serve as important diagnostic, prognostic and/or therapeutic markers. However, the substantial discrepancy in interpretation and reporting of these genomic abnormalities among testing labs creates challenges for patient management. Therefore, standardizing the curation, clinical interpretation and reporting of somatic alterations within the context of their diagnostic, prognostic and therapeutic significance in hematological cancers is critical. In January 2020, the ClinGen Somatic Cancer Clinical Domain working group formed the Hematological Cancer Taskforce (HCT) with a goal to undertake systematic curation and evidence-based clinical interpretation of genes/somatic variants associated with hematological malignancies. The HCT has recruited 32 multi-disciplinary experts including oncologists, molecular pathologists, clinical lab directors, genomic scientists and biocurators with expertise in hematological malignancies. In collaboration with the Clinical Interpretation of Variants in Cancer (CIViC) (civicdb.org) knowledgebase, variants from peer-reviewed publications are curated with editor review for clinical utility as evidence items. Monthly discussions based on these evidence items lead to the creation of summary variant assertions using the AMP/ASCO/CAP guidelines (Li M, et al., Journal of Molecular Diagnostics, 2017). The HCT is currently focused on expert curation and clinical interpretation of somatic variants in FLT3 (internal tandem duplication, tyrosine kinase domain and non tyrosine kinase domain variants) in acute myeloid leukemia (AML). Expert curation of gene fusions in Philadelphia chromosome-like acute lymphoblastic leukemia (Ph-like ALL) in collaboration with the ClinGen somatic pediatric cancer taskforce is currently underway. To date, the HCT has curated 45 evidence items from clinical and pre-clinical studies on the aforementioned genes/variants. In addition, three AMP Tier I, level A variant assertions of FLT3-ITD, D835 and I836, which predict response to Gilteritinib, an FDA-approved drug for relapsed or refractory AML, have been curated. In the future, the HCT plans to extend its focus on curation of BCR-ABL1 kinase domain mutations in chronic myeloid leukemia (CML). Based on the initial pilot curation phase, the HCT will develop gene-specific recommendations to standardize the reporting and interpretation of somatic variants to better assist clinical decisions and apply to become official ClinGen Somatic Expert Panels in each of these gene-disease domains. Disclosures Blombery: Novartis: Consultancy; Invivoscribe: Honoraria; Amgen: Consultancy; Janssen: Honoraria.
Expression of Adipocyte/Macrophage Fatty Acid–Binding Protein in Tumor-Associated Macrophages Promotes Breast Cancer Progression
Hao, Jiaqing , Yan, Fei , Zhang, Yuwen , Triplett, Ashley, Zhang, Ying , Schultz, Debra A., Sun, Yanwen , Zeng, Jun , Silverstein, Kevin A.T. , Zheng, Qi , Bernlohr, David , Cleary, Margot P. , Sauter, Edward R. , Liu, Shujun , Suttles, Jill, Li, Bing , Egilmez, Nejat K.

Mayo Clinic

Cancer Research | February 6, 2018 | Volume: 78 | Issue: 9 | Pages: 2343-2355

10.1158/0008-5472.can-17-2465 | PMID 29437708 Get It

Abstract Tumor-associated macrophages (TAM) play a critical role in cancer development and progression. However, the heterogeneity of TAM presents a major challenge to identify clinically relevant markers for protumor TAM. Here, we report that expression of adipocyte/macrophage fatty acid–binding protein (A-FABP) in TAM promotes breast cancer progression. Although upregulation of A-FABP was inversely associated with breast cancer survival, deficiency of A-FABP significantly reduced mammary tumor growth and metastasis. Furthermore, the protumor effect of A-FABP was mediated by TAM, in particular, in a subset of TAM with a CD11b+F4/80+MHCII−Ly6C− phenotype. A-FABP expression in TAM facilitated protumor IL6/STAT3 signaling through regulation of the NFκB/miR-29b pathway. Collectively, our results suggest A-FABP as a new functional marker for protumor TAM. Significance: These findings identify A-FABP as a functional marker for protumor macrophages, thus offering a new target for tumor immunotherapy. Cancer Res; 78(9); 2343–55. ©2018 AACR.
Deficiency of AMPK in CD8+ T cells suppresses their anti-tumor function by inducing protein phosphatase-mediated cell death
Rao, Enyu , Zhu, Ganqian , Hao, Jiaqing , Persson, Xuan-Mai T., Egilmez, Nejat K. , Suttles, Jill, Li, Bing , Zhang, Yuwen

Mayo Clinic

Oncotarget | September 15, 2015 | Volume: 6 | Issue: 10 | Pages: 7944-7958

10.18632/oncotarget.3501 | PMID 25760243 Get It

Genomic Organization and Expression Analysis of B7-H4, an Immune Inhibitory Molecule of the B7 Family
Choi, In-Hak, Zhu, Gefeng, Sica, Gabriel , Strome, Scott E. , Cheville, John C. , Lau, Julie S., Zhu, Yuwen , Flies, Dallas B. , Tamada, Koji , Chen, Lieping

Mayo Clinic

The Journal of Immunology | April 20, 2014 | Volume: 171 | Issue: 9 | Pages: 4650-4654

10.4049/jimmunol.171.9.4650 | PMID 14568939 Get It

Abstract B7-H4 is a recently identified B7 family member that negatively regulates T cell immunity by the inhibition of T cell proliferation, cytokine production, and cell cycle progression. In this study, we report that the genomic DNA of human B7-H4 is mapped on chromosome 1 comprised of six exons and five introns spanning 66 kb, of which exon 6 is used for alternative splicing to generate two different transcripts. Similar B7-H4 structure is also found in mouse genomic DNA in chromosome 3. A human B7-H4 pseudogene is identified in chromosome 20p11.1 with a single exon and two stop codons in the coding region. Immunohistochemistry analysis using B7-H4-specific mAb demonstrates that B7-H4 is not expressed on the majority of normal human tissues. In contrast, up to 85% (22 of 26) of ovarian cancer and 31% (5 of 16) of lung cancer tissues constitutively express B7-H4. Our results indicate a tight regulation of B7-H4 expression in the translational level in normal peripheral tissues and a potential role of B7-H4 in the evasion of tumor immunity.